atorvastatin + candesartan

Atorvastatin + candesartan is a fixed-dose combination of two small molecule drugs used for dual cardiovascular risk prevention. Atorvastatin is a statin that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced plasma cholesterol and LDL levels. Candesartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the Type-1 angiotensin II receptor (AT1R) in vascular smooth muscle and adrenal glands, resulting in vasodilation and decreased blood pressure[6]. The combination targets both dyslipidemia and hypertension, providing additive benefits for patients at risk of cardiovascular events[1][4]. Clinical studies indicate that this combination can inhibit progression of atherosclerosis more effectively than statin monotherapy in patients with coronary artery disease[4], and pharmacokinetic data support its safety when coadministered[1][5].

Brand names

Canvastin

Other names

atorvastatin + candesartan